Business Daily Media

Men's Weekly

.

Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

  • Written by PR Newswire

MELBOURNE, Australia, Jan. 20, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today announced that the first patient with metastatic castration-resistant prostate cancer...

Why I Decided to Build a Better Way to Build Homes

Why does building a home still feel like stepping into the unknown? In an industry where costs blow out and decisions come too late, certainty has...

Leonardo.Ai reveals new brand, expanding its creator-first platform for the next era of generative AI

The company has also launched its developer API to empower creators and builders to integrate AI into their workflows SYDNEY, Australia – 19 Febr...

Psychosocial injury risk starts inside workplace microcultures

Psychological injury is now one of the most expensive categories of workers compensation claims in Australia, with Safe Work Australia reporting t...

2025 Thryv Business and Consumer Report - Australian small businesses show grit under pressure

Australia’s small businesses are powering ahead with optimism, resilience and discipline, however, mounting pressures on costs, wellbeing and cons...

Security by Default: Why 2026 Will Force Organisations to Rethink Cloud and AI

financial accountability to how they run cloud and AI, according to leading Australian systems integrator, Brennan. Based on customer insights...

UNSW launches plan to help Aussie startups scale overseas

UNSW Launches Global Innovation Foundry to Scale 100 Australian Startups Internationally New initiative provides startups and spinouts with direc...